Our reporting shows this will be painful for many biopharma companies who rely on funds from the sale of PRVs. Speaking of money, AbbVie and Eli Lilly struck a pair of mid-size deals in hot spaces.

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie (NYSE:ABBV) in the last three months. The table below provides a concise overview of ...

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

Implants are biomedical materials or medical devices intended to replace a missing biological structure, or support or augment the function of an existing one. Examples of implants are prostheses ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

A European Commission committee is recommending AbbVie's Rinvoq for treatment of giant cell arteritis following Phase 3 clinical trial results that showed efficacy and safety in the inflammatory ...

In February 2025, a rumor spread online that Elon Musk, the technology mogul and public face of the new Department of Government Efficiency under U.S. President Donald Trump, has a penile implant. S ...

Since the publication of my article "Top 4 Immunology Stocks Poised For Growth In 2025," AbbVie's stock price (NYSE:ABBV) has risen by over 17%. The first reason is that the North Chicago-based ...